Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals, has launched Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial in the United States.
The launch expands the company's injectable portfolio in the US market and strengthens its presence in the institutional healthcare segment.
The newly launched product is a generic version of ProvayBlue Injection and has been approved as bioequivalent and therapeutically equivalent to the reference listed drug.
The launch enables Glenmark to participate in a niche injectable market within the US pharmaceutical sector.
According to IQVIA sales data cited by the company, the reference product market generated annual sales of approximately $19 million for the 12-month period ended April 2026.
The market size highlights the commercial opportunity available through the introduction of the generic formulation.
The launch adds another product to Glenmark's institutional medicines portfolio in the United States.
The company has been expanding its presence across hospital and healthcare institution-focused segments through new product introductions and portfolio diversification initiatives.
The US remains one of Glenmark's important international markets, and the company continues to focus on broadening its product offerings across therapeutic categories.
The latest launch forms part of Glenmark's strategy to enhance access to affordable medicines while strengthening its global generics business.
Read More: Glenmark Pharma Shares Rise After IGI Unveils New Solid Tumour Drug Candidate ISB 2301!
As of 17 June 2026, at 12:54 PM, Glenmark Pharmaceuticals share price was trading at ₹2,135.70 per share, reflecting a decline of 0.97% from the previous close.
Glenmark has launched Methylene Blue Injection USP in the US market, expanding its injectable medicines portfolio and providing access to a market valued at approximately $19 million annually. The launch further strengthens the company's presence in the institutional healthcare segment.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jun 17, 2026, 1:07 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
